Results 31 to 40 of about 193 (86)
A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19”
Pulmonary Circulation, Volume 15, Issue 2, April 2025.ABSTRACT Bufei huoxue capsules (BFHX), manufactured products of traditional Chinese medicine, have demonstrated anti‐inflammatory properties and efficacy against chronic pulmonary diseases and COVID‐19. This study was designed to further determine the clinical efficacy of BFHX in diverse patient subgroups during the convalescent phase of COVID‐19 ...
Chi Hou +24 more
wiley +1 more source
Sepsis: the evolution of molecular pathogenesis concepts and clinical management
MedComm, Volume 6, Issue 3, March 2025.(A) The innate and adaptive immune responses established during long‐term evolution can eliminate most invading microorganisms. (B) Sepsis only occurs when the balance is disrupted and the pathogen force overwhelms the host's defense force. (C) Only when the superposition of external forces (sensitive antimicrobial drugs) and internal forces ...
Zhongxue Feng +7 more
wiley +1 more source
Immunity, Inflammation and Disease, Volume 12, Issue 5, May 2024.(1) Dioscin improved the myocardial tissue damage of SIC rat. (2) Dioscin improved LPS‐decreased the activities of SOD, CAT, and GSH. (3) Overexpressed TLR4 promoted the Dioscin‐suppressed the viability of H9c2 cell. Abstract Background Dioscin has many pharmacological effects; however, its role in sepsis‐induced cardiomyopathy (SIC) is unknown ...
Meng Zhang +4 more
wiley +1 more source
Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial [PDF]
, 2016 Background: Severe pneumonia (SP) is a major complication of respiratory system diseases that is associated with high mortality and morbidity. If not treated correctly, it may rapidly lead to sepsis and multiple organ dysfunction syndrome.
Zhiqiao Feng +23 more
core +1 more source
Plant‐derived compounds as potential leads for new drug development targeting COVID‐19
Phytotherapy Research, Volume 38, Issue 3, Page 1522-1554, March 2024.Abstract COVID‐19, which was first identified in 2019 in Wuhan, China, is a respiratory illness caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Although some patients infected with COVID‐19 can remain asymptomatic, most experience a range of symptoms that can be mild to severe. Common symptoms include fever, cough,
Lingxiu Liu, Maxim Kapralov, Mark Ashton
wiley +1 more source
, 2020 The drug combination of biapenem (BIPM) and xuebijing injection (XBJ) is commonly applied for the treatment of sepsis in China. However, the potential synergistic mechanism is still enigmatic.
Ying-Ying Shi (8747094) +11 more
core +1 more source
Xuebijing injection alleviates liver injury by inhibiting secretory function of Kupffer cells in heat stroke rats [PDF]
, 2013 ObjectiveTo evaluate the effects of Xuebijing (XBJ) injection in heat stroke (HS) rats and to investigate the mechanisms underlying these effects.MethodsSixty anesthetized rats were randomized into three groups and intravenously injected twice daily for ...
Chen, Yi +7 more
core +1 more source
Food Safety and Health, Volume 2, Issue 1, Page 145-157, January 2024.Star anise possesses diverse bioactive compounds. Employing network pharmacology and molecular docking, we investigated the primary active constituents extracted via four methodologies, unveiling their key bioactive agents and preventive mechanisms against COVID‐19.
Ning Li +5 more
wiley +1 more source
, 2020 The drug combination of biapenem (BIPM) and xuebijing injection (XBJ) is commonly applied for the treatment of sepsis in China. However, the potential synergistic mechanism is still enigmatic.
Ying-Ying Shi (8747094) +11 more
core +1 more source
, 2020 The drug combination of biapenem (BIPM) and xuebijing injection (XBJ) is commonly applied for the treatment of sepsis in China. However, the potential synergistic mechanism is still enigmatic.
Ying-Ying Shi (8747094) +11 more
core +1 more source